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ABSTRACT 
Diabetes mellitus (DM) is a prothrombotic disease which is associated with a high risk for 
cardiovascular events, especially in type 2 DM (T2DM). The aim of this work is to contribute 
to the improvement of cardiovascular risk in DM. Patients with DM have reduced responses 
to antiplatelet treatment with aspirin, perhaps due to an increased platelet turnover, and this is 
associated with a poor outcome. Postprandial hyperglycemia is an independent risk factor for 
cardiovascular complications. 
We compared the laboratory responses to twice daily dosing of aspirin 75 mg, the regular 
once daily dose of 75 mg or a higher once daily dose of 320 mg in an open cross-over study 
in 25 patients with T2DM and micro/macrovascular complications, We found an improved 
response to 75 mg twice daily as compared to both once daily doses using two whole blood 
methods; impedance platelet aggregometry and the IMPACT-R cone and platelet analyzer. 
Both patients with a high and low platelet turnover could benefit from twice daily dose of 
aspirin. 
The role of postprandial hyperglycemia in postprandial platelet activation was examined in a 
randomized cross-over study comparing premeal insulin (0.1 and 0.2 U/kg insulin aspart) and 
placebo in 18 patients with T2DM. Platelet activation was studied in the fasting state, before 
and after normalizing glucose levels, and 90 min after a carbohydrate rich meal. Although 
postprandial glucose levels decreased after insulin injection, platelet activation increased. 
Glucose normalization with IV insulin aspart before the meal also resulted in platelet 
activation mainly via the thromboxane pathway as studied with the thromboxane analogue 
U46619 using flow cytometry. The postprandial platelet activation was correlated directly to 
insulin levels and inversely to glucose levels. We therefore concluded that postprandial 
platelet activation in T2DM is related to insulin rather than to glucose levels. 
The role of insulin in postprandial platelet activation was further investigated by comparing 
T1DM (n=11) and T2DM (n=9), without premeal insulin before and after a carbohydrate rich 
meal. T1DM patients, who had very high postprandial glucose levels due to inability to 
secrete insulin, had no platelet activation after the meal. These findings further support the 
role of insulin in postprandial platelet activation.  
Microparticles derived from platelets, monocytes and endothelial cells were formed after a 
carbohydrate meal in both patients with T1DM and T2DM in the above study. The 
microparticles had a prothrombotic potential (thrombin generation assay) which was related 
to phosphatidylserine and not to tissue factor expression. As opposed to the importance of 
insulin in postprandial platelet activation seen in T2DM, the procoagulant microparticles 
increased similarly or even more in T1DM. Therefore microparticle release may be related to 
hyperglycemia rather than hyperinsulinemia.  
This work suggests that twice daily dosing can improve the response to low-dose aspirin 
treatment in T2DM which might improve cardiovascular prognosis, and that liberal usage of 
premeal insulin may not benefit patients with T2DM as it contributes to postprandial platelet 
activation, and insulin treatment has been related to increased cardiovascular risk in DM. 
Postprandial platelet activation does not occur without premeal insulin in T1DM but should 
also be studied after insulin. Prothrombotic microparticle release however occurs in both 
T1DM and T2DM after the meal. 
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T2DM  Type 2 diabetes mellitus 
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1    INTRODUCTION 
1.1  General background  
Diabetes mellitus (DM) is a prothrombotic disease associated with inflammation and accelerated 
atherosclerosis. The prevalence of DM is increasing worldwide; 360 million people were 
estimated to have DM in 2011, 95% of them having DM Type 2 (T2DM), and the incidence of 
DM is rapidly increasing so that 552 million people are expected to have DM by 2030 (1). Type 
1 DM (T1DM) is an autoimmune disease leading to destruction of pancreatic beta cells and an 
absolute insulin deficiency, and usually occurs in young and slim people. T2DM, on the other 
hand, usually occurs in obese subjects in the context of a westernized lifestyle, with high fat diets 
and little exercise. T2DM patients are often overweight with an abdominal fat distribution, and 
they have insulin resistance with elevated plasma insulin levels. In early stages of the disease, 
impaired first phase insulin secretion leads to postprandial hyperglycemia (PPH), which is 
followed by a deteriorating second phase insulin response and persistent hyperglycemia in the 
fasting state in later stages (1). 
Macrovascular complications such as acute myocardial infarction and ischemic stroke are the 
leading causes of death in DM. Patients with T2DM have a 2-4 fold increased risk of suffering 
coronary artery disease, and their risk of suffering a myocardial infarction is similar to that of 
patients without diabetes who already had myocardial infarction (2) (3). DM further worsens the 
prognosis of patients with coronary artery disease, such as after a major ischemic event and after 
revascularization (4). 
 
1.2  Prothrombotic alterations in Diabetes Mellitus  
DM is associated with a hypercoagulable state which is multifactorial. There is enhanced 
thrombin generation by platelets, impaired fibrinolysis secondary to elevated levels of 
plasminogen activator inhibitor (PAI-1), and low grade inflammation leading to elevated levels 
of IL-6 and fibrinogen, and increased tissue factor expression in the endothelium (5).  
Platelets play an important role in the initiation and progression of atherothrombosis (6).  
Platelets in DM have an increased tendency toward adhesion and (7) and a high reactivity, 
meaning that they can easily be activated even with lower concentrations of agonists. The 
platelets in DM may have a higher turnover, they are "bigger" and they have more binding sites 
for agonists. Arachidonic acid (AA) metabolism is increased in DM and patients produce more of 
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the platelet agonist thromboxane A2 (TxA2) which is a positive feed-back mechanism in platelet-
dependent thrombosis. Platelets from diabetic patients seem to have "insulin resistance", and 
absence of an inhibitory effect of insulin as described further below.  There is decreased 
production of nitric oxide (NO) and prostacyclin (PGI2) by endothelial cells and there are also 
impaired responses to the antiplatelet and vasodilatory effects of NO and PGI2 in DM (8). 
 
1.3  Aspirin treatment in diabetes  
AA is metabolized in platelets to TxA2 which is a platelet aggregant and a vasoconstrictor, and in 
endothelial cells to PGI2 which is antiaggregatory and a vasodilator. Low-dose aspirin 
(acetylsalicylic acid) irreversibly inhibits the platelet cyclooxygenase, COX-1, and blocks the 
platelet-dependent production of TxA2. Low-dose aspirin is considered to act presystemically on 
platelets in the portal system with little systemic bioavailability and minimal effects on the 
endothelial production of PGI2 via COX-2. The balance between TxA2 and PGI2 production is 
important for the efficacy of aspirin as an antiplatelet drug. With high doses aspirin is able to 
inhibit PGI2 and shift the balance toward a more prothrombotic one, even though endothelial 
cells are able to synthetize new COX-2 (9). Greater than 95% inhibition of platelet-dependent 
TxA2 synthesis appears to be required for effective inhibition of Tx-dependent platelet 
aggregation (10). 
 
Low-dose aspirin treatment reduces morbidity and mortality in patients with acute coronary 
syndromes (ACS) and its use is clearly indicated in all such patients for secondary prevention, 
including patients with DM (1). Dual antiplatelet treatment with aspirin and the ADP blocker 
clopidogrel has further improved outcome in patients with ACS (11). However, DM patients 
have a higher risk for cardiovascular complications after ACS under dual antiplatelet treatment 
with aspirin and clopidogrel (12) and diabetic patients were shown to have reduced responses to 
both aspirin and clopidogrel (13-15), indicating that new approaches to antiplatelet treatment in 
DM are needed, and that diabetic patients might need more efficient platelet inhibition after ACS. 
Aspirin was previously recommended for primary prevention among all patients with DM above 
the age of 40, based on their increased cardiovascular risk (16). However, trials on primary 
prevention followed by several metaanalyses failed to show benefit from the use of aspirin in 
patients with DM, and the use of aspirin for primary prevention in DM has therefore been 
questioned (17-21).    
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Different mechanisms have been proposed to explain the reduced response to aspirin in patients 
with DM including increased TxA2 synthesis, glycation of platelet proteins which might compete 
with acetylation by aspirin, and a high platelet turnover (22).  
Platelets normally persist in the blood stream approximately 7-10 days. They appear in several 
sizes. When platelet turnover is high, the proportion of large/reticulated platelets is increased. 
Those platelets are more active. They contain mRNA and are capable of producing membrane 
and secretory proteins with potentially prothrombotic effects such as GPIIb/IIIa and COX-2 (23). 
In addition, aspirin, has a short half-life of only 20 min in blood and newly released platelets are 
likely to be unaffected during a large part of the normal 24 h dosing interval. Since ≈10% of the 
circulating platelets are newly formed each day in healthy subjects, some recovery of TxA2 
synthesis might occur within a 24-hour dosing interval. We previously found that inhibition of 
Tx-dependent platelet aggregation in whole blood by aspirin – even at high doses – was not fully 
sustained during 24 hours in normal subjects (24). 
 
Several recent studies have indicated that both healthy subjects and patients with coronary artery 
disease with increased platelet turnover may have reduced responses to antiplatelet drugs (23, 25-
26). Increased platelet turnover might result from either abnormal megakaryopoiesis or increased 
peripheral consumption by injured blood vessels (27). Patients with DM are of particular interest 
due to their high risk for cardiovascular events. The evidence for increased platelet turnover in 
DM is derived mainly from old studies, where accelerated entry of newly formed platelets 
(measured by platelet aggregation, thromboxane formation and ATP secretion) was observed in 
patients with DM and angiopathy compared to healthy subjects (28). The proportion of 
unblocked platelets at the end of a 24 hour dosing interval could thus be expected to be higher in 
such DM patients. We therefore suggested that aspirin given twice daily might be beneficial in 
patients with DM and angiopathy.   
 
1.4  Postprandial blood glucose  
Glucose begins to rise about 10 minutes after a meal due to the absorption of dietary 
carbohydrates. The postprandial blood glucose profile is determined by carbohydrate absorption, 
insulin and glucagon secretion, and their effects on glucose metabolism in the liver and 
peripheral tissues (29). The magnitude and time to peak of postprandial hyperglycemia (PPH) 
depend both on the composition of the meal and the subject. In non–diabetics, plasma glucose 
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levels peak 60 min after the meal, rarely exceed 7,8 mmol/L (140 mg/dl), and return to 
preprandial levels within 3 hours, even though  absorption of the ingested carbohydrates 
continues for at least 5-6 hours after a meal. In patients with T1DM who are unable to secrete 
insulin, the postprandial glucose levels depend on the type, dose and route of administration of 
exogenous insulin. In T2DM patients the peak insulin levels are delayed and insufficient to 
control PPH. Abnormalities in glucagon secretion, hepatic glucose uptake, suppression of 
glucose production and peripheral glucose uptake all contribute to the delayed and higher 
postprandial glucose levels in both T1DM and T2DM patients (29). Postprandial glucose levels 
are usually measured 90-120 minutes after the meal and should be below 10 mmol/L (180 
mg/dL) to achieve adequate metabolic control with  HbA1c levels in the target range of below 
7% (30-31). PPH develops early in the course of the disease in  T2DM patients, and is thought to 
be an independent risk factor for cardiovascular complications in DM (32-33). PPH is associated 
with increased production of free radicals (34), endothelial dysfunction (35-36), and platelet 
activation (37-39).  
 
Rapidly acting “meal insulin”, as well as several other new drugs targeting PPH have been 
developed in recent years (33). Ceriello et al have shown that insulin aspart reduces PPH as 
compared to soluble insulin, and that this improves endothelial dysfunction in DM patients (36). 
However, it is still controversial whether achieving established PPH targets add benefit to CVD 
outcome. (32, 40-42). 
 
Hyperglycemia has been considered to be a major cause of the platelet hyperactivity in DM 
(8,38,43). Several studies, including work from our laboratory, have shown that high blood 
glucose can increase platelet reactivity via an elevation of osmolality (44-45). We also found that 
a carbohydrate rich meal increases platelet activation and platelet–leukocyte conjugation in 
response to stimulation with ADP (39) and, in particular, with the thromboxane A2 analogue 
U46619 (37) in T2DM patients. Since healthy controls did not develop PPH and did not show 
increased platelet reactivity after the same meal (37), it was hypothesised that the postprandial 
platelet activation was related to the hyperglycemia. Santilli et al (38) showed that acarbose 
treatment, which attenuates PPH, reduced the urinary Tx metabolite excretion in patients with 
T2DM and that this effect was correlated to changes in PPH. However, treatment with the oral 
hypoglycemic agents repaglinide or glibenclamide reduced PPH only mildly, and did not 
counteract the postprandial platelet activation in our previous studies (37,39). Thus we speculated 
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that a more aggressive approach is needed to control the PPH and, possibly, the accompanying 
platelet activation after a meal intake.   
 
1.5  Microparticles 
Microparticles (MPs) found in the blood stream are bioactive sub-micron (0.1–1 µm) membrane 
vesicles shed from activated and apoptotic cells in culture and in vivo. They are detectable in 
healthy subjects but their numbers are greatly increased in a variety of diseases such as cancer, 
venous thromboembolism, coronary artery or cerebrovascular disease, hypertension and diabetes 
(46, 47). MPs are derived from a variety of cell types such as platelets, monocytes, endothelial 
cells and red blood cells. They bear surface antigens from their parent cells and express anionic 
phospholipids such as phosphatidylserine (PS). Their origins can be identified by their surface 
antigens using flow cytometry. For example, in study number IV we identified platelet derived 
MPs by the integrin alpha IIb (CD41) of the GPIIb/IIIa complex, endothelial derived MPs by 
VE-cadherin (CD144), activated endothelial derived MPs by E-selectin (CD62E), and monocyte 
derived MPs by CD14.  
 
Platelet derived MPs are the most abundant and can be identified in both healthy and sick 
patients, while monocyte derived MPs are low or even undetectable in healthy subjects (46). MPs 
are believed to support coagulation and promote thrombin generation, and it was recently shown 
that MPs from platelets and monocytes differentially modulate clot formation, structure and 
stability, suggesting that the various MPs may provide unique contributions to thrombosis (46). 
 
The number of MPs in plasma is elevated in patients with DM compared to healthy subjects (48-
49) and among diabetic patients they are increased in patients with vascular complications (50) 
and they might contribute to the increased thrombotic risk in those patients. There is very limited 
data on MPs in the postprandial phase. Endothelial derived microparticles are increased after a fat 
rich meal in patients with T2DM, but there is no information regarding other types of MPs or 
their procoagulant potential in this setting (51). 
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2    AIMS OF THE PROJECT 
The overall aim of this work is to contribute to the improvement of prevention and treatment of 
cardiovascular risk in DM. Specific aims in this project are:  
Study 1. To evaluate whether twice daily dosing of aspirin improves its antiplatelet effect as 
compared to the usual once daily dosing in high risk patients with T2DM and micro- and/or 
macrovascular complications.  
Study 2. To evaluate if the platelet activation seen after a carbohydrate rich meal in T2DM 
patients is related to their postprandial hyperglycemia, and thus can be attenuated by premeal 
insulin treatment. 
Study 3. To compare postprandial platelet activation in patients with T1DM and T2DM, when no 
insulin is given prior to the meal, in order to further investigate the role of insulin in posprandial 
platelet activation.  
Study 4. To investigate whether intake of a carbohydrate rich meal has an effect on microparticle 
(MP) production and procoagulant activity in diabetes, and whether those parameters differ 
between patients with T1DM and T2DM.  
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3    STUDY DESIGN 
3.1  Study population  
Patients were recruited from the Diabetology and Cardiology outpatient clinics of the Karolinska 
University Hospital.  
For study 1 we included 25 patients with T2DM, 51-75 years old with microvascular 
complications (retinopathy, neuropathy or nephropathy) and/or patients with stable 
macrovascular complications (ischemic heart disease, cerebrovascular disease or peripheral 
vascular disease) who had not had any clinical event in the preceding 6 months. They were either 
high risk patients who already took aspirin for cardiovascular protection (n= 21) or had multiple 
risk factors and an indication for aspirin treatment according to the AHA/ADA guidelines at the 
time (16).  
For study 2 we included 18 patients with T2DM, 51-69 years old, who did not have 
macrovascular complications and did not use antiplatelet drugs that may interfere with meal 
effects on platelets.  
For studies 3-4, nine T2DM patients with the same characteristics as in study 2 were compared to 
11 patients with T1DM who were 40-72 years old, did not take antiplatelet drugs, did not have 
insulin secretion, and had a BMI below 26 kg/m
2
.  
For all studies we included patients who had HbA1c levels below 90 mmol/mol (IFCC method), 
or 10.4 % (NGSP method) to avoid very poorly controlled and unstable patients. The patients 
abstained from food, tobacco or nicotine on the days of experiments. For the "meal studies" 
(studies 2-4), patients who took basal insulin were instructed to take half of the evening dose of 
insulin to avoid problems with hypoglycemia without eating in the morning. The patients took no 
glucose lowering medications in the morning of the experiments, to avoid hypoglycemia or 
effects of oral medications on postprandial glucose.  All patients had good antecubital veins 
which is important for the minimization of sampling artifacts in platelet function testing and they 
all rested for 30 minutes before the first blood draw.  
3.2  Study design  
Study 1 was a randomized, open, cross-over study with three visits.  Patients took three different 
doses of aspirin for at least two weeks each: the regular dose of 75 mg once daily (OD), an 
intermediate dose of 320 mg OD (previously often used in the USA)  or 75 mg twice daily (BID) 
according to a randomization list.  
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Study 2 was a randomized, double-blind, cross-over study with three visits. At each visit  the 
premeal glucose levels were standardized with IV insulin aspart to achieve ≈6 mmol/L. Fifteen 
minutes after achieving this target, one of 3 subcutaneous injections were given according to a 
randomization list (saline as placebo, insulin aspart 0.1U/kg or insulin aspart 0.2U/kg). Only the 
nurse giving the injection had the randomization list, and both the researchers and the patients 
were unaware of the content of the injection. Immediately after the injection patients ingested the 
same carbohydrate rich meal prepared by the hospital kitchen during 15 min. The meal  
contained 620Kcal, 54% carbohydrates, 30% fat 16% protein, and 6.5 grams of fiber. (chicken, 
rice, boiled vegetables, a carrot salad, bread, margarine and an apple). Three sets of blood 
samples for platelet function tests were taken:  before and 15 minutes after glucose 
standardization, and 90 minutes after the meal (Figure 1). Samples for glucose, insulin and c-
peptide measurements were taken together with platelet functions tests and also immediately, 15, 
30, 45 and 60 minutes after the meal.  
Study 3+4 was a single visit, comparing T1DM and T2DM patients without premeal insulin. 
Platelet function (study 3) and MPs (study 4) were measured at baseline (after 30 min rest) and 
90 minutes after the same meal as in study 2.  
 
 
  Figure 1: Study 2 design  
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4    METHODS  
4.1  Responses to aspirin treatment  
Several different methods have been used to test laboratory responses to aspirin treatment. There 
is no “gold standard”, although aggregometry in platelet rich plasma (PRP) is the one most 
widely accepted as such. Each method has its advantages and disadvantages, and they are more 
or less directly related to platelet COX-1 function. The following methods were used in study 1: 
Turbidimetric aggregometry in platelet rich plasma  
Turbidimetric aggregometry in PRP according to Born (52), which is often called light 
transmission aggregometry (LTA), measures the increase of light transmission through platelet 
rich plasma when platelets aggregate in response to an agonist. This is the historical gold 
standard and has been widely used to measure responses to aspirin. It has been correlated with 
clinical events (53). When stimulating platelet aggregation in PRP with AA it specifically 
reflects platelet COX-1 inhibition by aspirin. Blood was anticoagulated with citrate (final 
concentration of 0.38%) and centrifuged at 190 x g for 10 minutes to prepare PRP and 1400 x g 
for 10 min to obtain platelet poor plasma (PPP). The following agonists were used: AA 0.5 and 
1 mmol/L (Sigma Chemical Co, St. Louis, MO , USA) (24), collagen 1 µg/mL (type 1; Horm, 
Nycomed Arzneimittel, Munich, Germany ), and  ADP 5 µmol/L (Sigma). 
Impedance aggregometry  
Impedance aggregometry is also called whole blood aggregometry and measures the change in 
electrical impedance between two electrodes when platelets are aggregated by an agonist (54). 
The advantage of this method is that it is performed in whole blood, where interactions 
between platelets and red and white blood cells take place and might influence aggregation. For 
study 1 we used the Chrono-log model 570-VS Four Sample. The blood was anticoagulated 
with hirudin to maintain normal extracellular calcium levels and diluted 1:1 with physiological 
saline. The following agonists were used: AA (Sigma) at final concentrations of 0.5 and 1 
mmol/L, and collagen (type 1; Horm, Nycomed) at a final concentration of 1 µg/mL. The 
amplitude of aggregation was measured after 6 minutes and is expressed in Ohms. For study 3 
we used multiple electrode aggregometry with the Multiplate
®
 technology and reagents (Roche 
Diagnostics International, Rotkreuz, Switzerland ). Agonists used were:
 
ADP (6.5 µmol/L; 
ADPtest
®
), AA (0.5 mmol/L; ASPItest
®
), collagen (3.2 µg/mL; COLtest
®
), as well as U46619 
(0.3 µmol/L; no commercial test). Results are expressed as area under the curve (AU/min).
 
 
The  IMPACT-R Cone and Plate(let) Analyser (CPA)  
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The IMPACT-R Cone and Plate(let) Analyser (CPA) (Diamed, Cresier, Switzerland) is a point 
of care method for the monitoring of platelet adhesion and aggregation in whole blood under 
shear stress (55). It has been modified to test responses to anti-platelet drugs and showed a 
good correlation with turbidimetric aggregometry (56). 130 l of citrated whole blood is placed 
on a polystyrene well and subjected to an arterial shear rate of 1800 s
-1 
for 2 minutes. Adhesion 
of single platelets and platelet aggregates to the surface is measured as % surface coverage 
(%SC) of adhered platelets. To evaluate the response to aspirin, samples were preincubated 
with AA 0.32 mM for 1 minute under gentle mixing at 10 RPM. In patients with a poor 
response to aspirin, platelet microaggregates are formed during preincubation resulting in 
adhesion refractoriness and decreased platelet adhesion to the well (55), while in patients with 
good responses to aspirin, microaggregates are not formed and platelet adhesion to the well is 
normal. Therefore, increased SC% in this method represents a good response to aspirin as 
opposed to PRP or whole blood aggregometry in which reduced platelet aggregation reflects a 
good response to aspirin. Patients with acute coronary syndromes had a high rate of 
unresponsiveness to aspirin by both tubidimetric aggregometry and the IMPACT-R, and this 
was related to a poor clinical outcome (57).  
Analysis of 11-dehydro-thromboxane B2 in urine:  
TxA2 is the major product of AA in platelets (58). TxA2 is unstable and is rapidly converted to 
TxB2 which is further metabolized to stable metabolites including the major metabolite 11-
dehydro-TxB2. The urinary excretion of 11-dehydro-TxB2  thus reflects thromboxane 
generation and platelet activation (59-60) and has been correlated with clinical events (61). 11-
dehydro-TxB2 excretion in urine depends directly on the function of aspirin’s therapeutic 
target, COX-1, but is not platelet specific, as other cells like monocytes and 
polymorphonuclear cells can produce thromboxane. Approximately 80% of 11-dehydro-TxB2 
excreted in the urine is platelet derived and 20% is of non-platelet origin (24, 62) Urinary 11-
dehydro-TxB2 was measured by enzyme immunoassay (Cayman Chemicals, Ann Arbor, USA) 
using a sample work–up procedure previously described and validated by us (24,63). Results 
are expressed in relation to creatinine excretion. Measurements were performed in morning 
urine to obtain an index of Tx production toward the end of the dosing interval.  
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4.2  Platelet turnover  
Reticulated platelets 
Reticulated platelets are young and large platelets that contain RNA, and a high percentage of 
reticulated platelets indicate a high platelet turnover. Poor responses to aspirin treatment are 
associated with higher percentages of reticulated, less mature platelets (23, 64).  Measurements 
in study 1 were made by flow cytometry (Beckman-Coulter EPICS XL-MCL flow cytometer) 
after incubation of blood with thiazole orange (Retic-COUNT 
TM
; Becton Dickenson, San Jose, 
CA, USA), a fluorescent dye that permeates the plasma membrane and binds to RNA (65).  
Mean platelet volume 
Mean platelet volume (MPV) is positively correlated with platelet turnover (66), and was 
measured in EDTA anticoagulated blood using a MICROS 60 cell counter (ABX Diagnostics, 
Montpellier, France).  
 
4.3  Assessment of platelet activation (studies 2-3) and microparticles (study 4) by 
flow cytometry   
P-selectin (CD62) is a protein stored in  granules of platelets. Upon activation of platelet 
secretion P-selectin translocates to the plasma membrane and can serve as a marker for platelet 
activation. Platelet activation through different pathways also results in a conformational 
change in the GPIIb/IIIa receptor, which enables it to bind fibrinogen and form platelet 
aggregates. In addition, leukocytes – predominantly monocytes and polymorphonuclear 
neutrophils – can bind activated platelets via P-selectin glycoprotein 1 ligand (PSGL-1) on 
leukocytes and P-selectin on platelets. Platelet–leukocyte aggregates are also considered as 
markers for platelet activation (67).  
Flow cytometric procedure: Aliquots of 5l of citrated whole blood were added to Hepes-
buffered saline containing appropriately diluted fluorescent monoclonal antibodies and incubated 
at room temperature for 20 min. After incubation, the samples were fixed with 0.5% (v/v) 
formaldehyde saline before flow cytometric analysis. Analyses were performed with a Beckman-
Coulter EPICS XL-MCL flow cytometer. Platelets were identified by their light scattering signal 
and staining with fluorescein isothiocyanate (FITC) conjugated anti-CD42a (GPIX) MAb 
(Becton Dickenson), P-selectin positive platelets by phycoerythrin(PE)-conjugated anti CD62 
(Becton Dickenson), and fibrinogen binding by FITC-conjugated polyclonal rabbit anti-human 
fibrinogen antibodies (DAKO, Glostrup, Danmark). Leukocytes were identified by anti CD45-PE 
(Beckman Coulter), and then further discriminated by their side scatter characteristics into 
lymphocytes, monocytes and neutrophils (68).  Monocytes were also identified by anti CD14-
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PC5 (Beckman Coulter).  For platelet-leukocyte aggregate analysis, leukocytes were subjected to 
two-color analysis (RPE-CD45 versus FITC-CD42a).  
 
Results are expressed as percentages of platelets expressing P-selectin, percentages of platelets 
binding fibrinogen, and percentages of leukocytes binding platelets in the total or subtype 
leukocyte population.  
 
4.4  Microparticles  
Platelet free plasma was obtained by high speed centrifugation of PPP that had been stored at -
80
o
C (69). MPs were measured by flow cytometry using a Beckman Gallios instrument 
(Beckman Coulter, Brea, CA, USA). The MP gate in flow cytometry was determined using 
Megamix beads. MPs were defined as particles less than 1.0 µm in size and negative to 
phalloidin (to exclude cell membrane fragments). MPs from all cell origins binding lactadherin 
were defined as posphatidylserine positive (PS
+
). Platelet-MPs (PMPs), were defined as 
PS
+
CD41
+
, endothelial-MPs (EMPs) as PS
+
CD144
+ 
or PS
+
CD62E
+
 (E-selectin positive), and 
monocyte-MPs (MMPs) as PS
+
CD14
+
. Further phenotyping included measurements of tissue 
factor (TF) (CD142) on PMPs, EMPs and MMPs, and P-selectin (CD62P) expression on PMPs. 
The absolute numbers of MPs were calculated by the following formula: (MPs counted x 
standard beads/L)/standard beads counted. Data are expressed as 10
6
 MPs/L. 
 
4.5  Thrombin generation  
The procoagulant potential of MPs in vitro was measured by a calibrated automated 
thrombogram (CAT) technique (70). High speed centrifugation of PPP was used to obtain MP-
enriched pellets (20 800 g for 45 min at RT). The pellet was then added to previously centrifuged 
normal pool plasma. Thrombin generation was measured during 60 minutes at 37°C according to 
instructions from the manufacturer of the equipment (Thrombinoscope BV, Maastricht, the 
Netherlands). The calculated area under the curve represents the total amount of thrombin 
generated over time, and is called endogenous thrombin potential (ETP). Time to the start of 
thrombin generation is the lag time, the maximal concentration of thrombin generated is called 
peak thrombin and the time to maximal thrombin generation is called time to peak.  
In order to further investigate the mechanisms of action involved in MP-induced thrombin 
generation, experiments were also performed after the addition of an antibody against TF (40 
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ng/mL, monoclonal anti-human tissue factor IgG, Sekisui Diagnostics, LLC, MA, USA) or 
incubation with lactadherin 30 µmol/L (purified lactadherin, Haematologic Technologies, 
Vermont, USA) which blocks the negatively charged surface by binding to PS. 
 
4.6  Urinary 8-isoprostane 
Urine samples for measurements of 8-isoprostane (8-iso prostaglandin F2) excretion, a measure 
of reactive oxygen species (ROS) and lipid peroxidation analysed by an enzyme immunoassay 
kit (Cayman Chemical , Ann Arbor, MI, USA), were obtained before and 90 min after the meal 
intake. Butyrated  ydroxyl toluene (0.005% final concentration) was added to prevent oxidative 
degradation of the analyte, and samples were stored at -80
o
C before analysis. The 8-isoprostane 
excretion rate is expressed as ng/nmol creatinine. 
 
4.7  Statistical analysis 
Continuous data were compared by repeated measures ANOVA, with Fisher´s post hoc testing to 
control for multiplicity. Differences between two groups of patients were analysed by Student´s 
unpaired t-test for continuous variables for uncorrected means (after validation for normal 
distribution by the Shapiro-Wilk test), or the chi square test for non-continuous variables. Trend 
analysis was performed by means of regression analysis. Mean values and standard deviation are 
given for studies 1 and 2, and errors of the mean for studies 3-4 are given unless otherwise stated. 
Analyses were performed using STATISTICA software (StatSoft, Tulsa, OK) and a p-value 
<0.05 was considered to indicate a statistically significant difference.
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5    RESULTS  
5.1  Study 1:  
We found better platelet inhibition with BID compared to OD dosing of aspirin in patients with 
T2DM and micro/macrovascular complications. Improved inhibition of Tx dependent platelet 
activation in whole blood was observed by two methods.  
Using impedance aggregometry aspirin 75 mg BID reduced AA included platelet aggregation in 
whole blood by a mean of 22% compared to the regular dose of 75 mg OD (from 12.6±3.5 to 
9.7±4.6 Ohms; p=0.003) and by 9% compared to aspirin 320 mg OD (from 12.6±3.5 to 9.7±4.6 
Ohms; p=0.003). Aspirin 75 mg BID also reduced collagen induced whole blood platelet 
aggregation by a mean of 16% (from 14.6±5.0 to 12.2±5.4 Ohms; p=0.02). The higher aspirin 
dose of 320 mg OD also reduced platelet aggregation in whole blood as compared to 75 mg OD, 
although to a lesser extent than did BID dosing.  AA induced aggregation decreased by a mean of 
13% (from 14.6±5 to 12.7±5.3; p=0.02) and collagen induced aggregation by a mean of 9% 
(from 12.6±3.5 to 11.5±4.2 Ohms; p=0.05) with 320 mg OD (Figure 2).  
With shear induced platelet activation, i.e., when using the IMPACR-R CPA method after 
incubation with AA, aspirin 75 mg BID increased the %SC by a mean of 20% as compared to 75 
mg OD (from 3.4±1.6 % to 4.1±2.2%; p=0.05) indicating a better response to the BID dose. The 
%SC response to 320 mg OD was intermediate (and not significantly different from either 75 mg 
dose regimen) (Figure 3). 
 
 
Figure 2: Responses to agonist stimulation using impedance aggregometry in whole blood (WBA). AA; 
arachidonic acid 0.5 mM, Coll; collagen 1 g/ml. 
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Figure 3: Surface coverage (%) after preincubation with arachidonic acid (AA) 0.32 mM in the IMPACT–
R test 
All patients had good responses to aspirin treatment with turbidimetric aggregometry in PRP. 
Platelet aggregation with AA 0.5mM was markedly reduced on all occasions with no differences 
between the doses: 2.9±1.4% with 75 mg OD, 3.1±1.4% with 75 mg BID and 3.4±3.4% with 320 
mg OD. There was high platelet reactivity to both ADP and collagen with no differences on the 
three occasions; mean ADP aggregation was 80±14%, 81±13% and 78±13%, and mean collagen 
induced aggregation 58±22%, 57±19% and 52±18% when treating with 75 mg OD, 75 mg BID 
and 320 mg OD, respectively.  
Urinary 11-dehydroTxB2 decreased with 320 mg OD as compared to 75 mg OD; (from 
30.8±11.3 to 25.9±7.5 ng/mmol creatinine, p=0.002), but was not significantly reduced by 75 mg 
BID (from 30.8±11.3 to 27.8±10.9; p=0.07).     
There was a very good correlation between the two measures of platelet turnover; percent 
reticulated platelets and mean platelet volume; R
2
=0.74 (Figure 4). However, improvements in 
platelet responses with BID treatment were not correlated with platelet turnover, as both patients 
with low and high turnover could benefit from BID aspirin treatment (see Figure 2 in paper I). 
 
Figure 4: Correlation between % reticulated platelets and mean platelet volume.  
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5.2  Study 2:  
Patients arrived at the laboratory three times in the fasting state. Their fasting glucose levels were 
high and comparable at the three visits (mean levels between 8.9-9.4 mmol/L). Premeal glucose 
normalization and standardization with IV insulin infusion successfully reduced the glucose 
levels to mean values of 5.3-5.6 mmol/L which did not differ between the visits. 90 min after the 
meal glucose levels increased on all three occasions, with the highest levels after placebo 
(11.7±0.5 mmol/L). Compared to placebo the postprandial glucose levels were reduced to 
9.9±0.4 mmol/L (p=0.002) with 0.1 U/kg and to 8.7±0.5 mmol/L (p<0.001) with 0.2 U/kg insulin 
aspart (Figure 5). 
Insulin levels in plasma were also comparable on the three occasions in the fasting state (mean 
levels between 34.3-36.8 U/mL), and they increased similarly on all occasions after IV insulin 
infusion (to mean levels between 47.3-47.9U/mL). Postprandial insulin levels increased dose-
dependently after the administration of meal insulin - highest with insulin aspart 0.2U/kg 
(109.7±74.2U/mL), followed by 0.1U/kg (94.8±72.4U/mL) and placebo (61.9±40U/mL) 
(Figure 5). 
   
 
 
 
 
 
 
 
 
  
Figure 5: Mean concentrations (± SEM)  for 
plasma (P) glucose and insulin. 
Measurements were performed in 18 
patients before (B1) and after (B2) glucose 
standardization by insulin infusion (if 
needed) and 90 min after the meal (PP). 
Premeal treatments were placebo (solid 
lines), insulin aspart 0.1 units/kg (dashed 
lines) and 0.2 units/kg (dotted lines).  
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The platelet activation markers P-selectin and fibrinogen binding, and responses to agonist 
stimulation did not differ either before or after the glucose normalization procedure that preceded 
the meal intake on the three occasions. 
Platelets were activated after the premeal IV infusion of insulin. P- selectin positive platelets 
increased after insulin infusion both without agonist stimulation (+10%), and with ADP (+7.5%) 
or U46619 stimulation (+67%; from 19.1±13.7 to 31.7±21% P-selectin positive platelets).  
Platelets were activated after the meal on all three occasions. Platelet activation was markedly 
increased postprandially with the thromboxane A2 analogue U46619, and mildly so with ADP. 
There was no meal effect with Collagen Related Peptide (a GPVI agonist). The meal itself 
activated platelets (after placebo injection): U46619 induced P-selectin expression increased by 
23% (p=0.02) (Figure 6), and ADP induced P-selectin expression increased by 5% (p=0.005). 
However, after insulin injections, when glucose levels reduced, platelets were more markedly 
activated, with no difference between the two insulin doses. P-selectin expression increased 
without agonist stimulation by 10-15% with the two insulin doses, by 54-57% after stimulation 
with U46619 and by 5-9% after stimulation with ADP. U46619 induced fibrinogen binding 
increased by 46-49% with premeal insulin (Figure 6). However, fibrinogen binding was 
decreased by 5-8% after stimulation with ADP.  
Postprandial platelet activation was inversely correlated with glucose levels and positively 
correlated with insulin levels (Figure 7). 
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Figure 6: Platelet P-selectin expression and fibrinogen binding expressed as percentage of positive 
platelets without (rest) and with stimulation with the TxA2 agonist U46619 (0.3 mol/L). Measurements 
were performed before (white bars) and after (gray bars) glucose standardization with IV insulin aspart, 
and 90 min after the meal (black bars).  
 
Figure 7: Correlations between postprandial glucose (left) and insulin responses (right) and platelet P-
selectin responses to U46619.  
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5.3  Study 3:  
Patients with T1DM or T2DM arrived at the laboratory in the fasting state for a single visit and 
had the same meal as in study 2 without premeal insulin. Before the meal patients with T1DM 
and T2DM had similar fasting glucose and insulin levels and the platelet activation markers P-
selectin and fibrinogen binding did not differ between T1DM and T2DM. Platelet-leukocyte 
aggregates were elevated in T1DM compared to T2DM. Meal intake increased glucose levels in 
both groups, but more markedly so in T1DM (from 7.9±0.7 before meal to 11.6±0.6 mmol/L 90 
min after meal in T2DM and from 9.2±0.85 to 21.3±1.6 in T1DM; p<0.001 for group difference). 
Postprandial insulin levels increased as expected in T2DM and did not change in T1DM (figure 
8). 
 
Figure 8: Mean concentrations (± SEM) for plasma (P) glucose and insulin. Measurements were 
performed in patients with T1DM (n=11, rhomboid line) or T2DM (n=9, square line) before and up to 90 
min after the meal. No premeal insulin was given. 
 
Postprandial platelet activation occurred as expected in T2DM but not in T1DM patients. Platelet 
P-selectin expression stimulated by U46619 was approximately doubled in T2DM but unchanged 
in T1DM (p=0.003 for group difference) (figure 9). ADP-induced P-selectin expression was also 
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increased after the meal in T2DM only, although to a lesser degree than with U46619 (from 
52.7±15.9 to 57.8±16.6; p=0.006 for group difference). 
Fibrinogen binding in resting platelets did not increase after the meal in either patient group but 
the response to stimulation by U46619 was mildly enhanced (p=0.03; no significant group 
difference) and the response to ADP stimulation was mildly decreased, more so in T2DM (from 
60.5±20 to 52.5±21%) than in T1DM (from 62.3±11 to 59.7±12%; p=0.01 for group difference). 
 
Figure 9: Platelet activation stimulated by the thromboxane analog U46619 before (black columns) and 
after the meal (hatched columns) in T1DM and T2DM patients. P-selectin expression (% positive 
platelets, panel a) and platelet-leukocyte aggregate formation (CD14 PLA; % positive, panel b) measured 
by flow cytometry, and whole blood aggregometry (WBA) using the Multiplate® technique (AU x min; 
panel c). Mean values ±SEM. 
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Hemoglobin , WBC and platelet counts did not differ between T1DM and T2DM either before or 
after the meal, therefore the two groups were analyzed together. The meal intake induced an 
increment in total WBC, from 5.1±0,1 to 5.5±0.3 (p=0.009). This resulted from an increment of 
neutrophils (from 2.9±0.2 to 3.4±0.2; p<0.001) whereas lymphocytes and monocytes decreased 
slightly (lymphocytes from 1.61±0.09 to 1.51±0.1; p=0.03, and monocytes from 0.64±0.04 to 
0.59±0.05; p=0.03) after the meal. There was also a slight but significant decrease in platelet 
counts (from 226±11 to 217±9; p=0.009). Hemoglobin levels did not change after the meal.  
All subtypes of PLAs except platelet-lymphocyte aggregates were elevated in T1DM compared 
to T2DM before the meal. Thus, platelet-monocyte and platelet-neutrophil aggregates were 
7.0±2.5% and 4.1±1.5% in T1DM versus 4.3±1.9% and 2.9±0.8% in T2DM (p<0.05 for both 
group differences). However, increased responses to U46619 stimulation after the meal were 
observed in the T2DM group only. For example, platelet-monocyte aggregates stimulated by 
U46619 were unchanged at 37.2±6.3% in T1DM but increased from 25.1±5.0% to 46.1±8.8% 
with U46619 after the meal in T2DM (p<0.001 for group difference) (Figure 9). After the meal 
U46619 also increased platelet-lymphocyte aggregates (from 2.0±0.3 to 3.1±0.5%; p=0.02) and 
platelet-neutrophil aggregates (from 13.56±3.0 to 28.4±6.8%; p=0.01) in the T2DM group, but 
there were no meal effects on any PLA subtype in the T1DM group. (p<0.01 for group 
differences).  
Platelet aggregation in whole blood stimulated by U46619 increased by 14% after the meal in T2DM 
(from 768±41 to 873±27.6 AUC; within group p=0.02) but not in T1DM (from 691±41 to 727±38 
AUC) (figure 9). No postprandial enhancements were observed with ADP, arachidonic acid or 
collagen in either T1DM or T2DM. 
In vitro incubation of blood samples with 100 µU/Ml insulin increased platelet P-selectin 
expression by ≈10% both in resting and U46619 stimulated platelets (p<0.005 for both; no group 
differences) before the meal. After the meal the responses to insulin in vitro were retained in 
resting samples (p<0.01) but blunted with U46619 stimulation, especially in the T2DM group 
which had high endogenous insulin levels after the meal (resulting in no significant overall 
effect) (Figure 10). 
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Figure 10: U46619 induced platelet P-selectin expressed as percentage of positive platelets, before and 90 
min after the meal, without and with in vitro incubation with insulin (100 µU/Ml, 3 min) in patients with 
T1DM and T2DM.     
 
The urinary excretion of 8-isoprostane did not differ between T1DM and T2DM patients before 
the meal (96±13 vs 96±36 ng/mmol creatinine), and did not change 90 min after the meal 
(103±25 vs 94±28 ng/mmol creatinine).   
 
5.4  Study 4:  
Microparticle counts (total PS
+ 
MPs, PMPs, EMPs and MMPs) did not differ significantly 
between T1DM and T2DM before the meal. After the meal MPs derived from all cell origins 
increased in both groups with some differences in platelet derived MPs. The total number of PS
+ 
MPs increased by 39-40% in T2DM and T1DM, monocyte derived MPs carrying TF increased 
by 164% and 135% in T1DM and T2DM patients, respectively. Endothelial derived MPs 
carrying E-selectin increased in both groups (by 96% in T1DM and 59% in T2DM) while PS
+
 
and TF
+
 EMPs did not change in either group. All types of platelet derived MPs, i.e., PS
+
, P-
selectin
+
, and TF
+
 PMPs,
 
increased in T1DM (by 83%, 115% and 157%, respectively) while only 
TF+ PMPs increased in T2DM (by 78%) (Table 1). 
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Table 1: Mean concentrations (x 10
6
/L)  of microparticles (MPs) derived from platelets (PMPs), 
endothelial cells (EMPs) and monocytes (MMPs). Phosphatidylserine (PS) positive MPs were identified 
with lactadherin (Lac). CD62P = P-selectin; CD62E = E-selectin; CD142 = tissue factor (TF); CD142 = 
VE-cadherin (correct?). The ratio after/before indicates the size of the meal effect for each variable within 
the T1DM and T2DM groups. Two factor repeated measures ANOVAs were used to analyze overall 
group differences and overall meal effects; there were no significant interaction terms for group x meal 
effect. * p<0.05; ** p<0.01; *** p<0.001 for meal effects within groups 
  
Meal intake increased MP-induced thrombin generation in normal platelet poor plasma in the two 
groups and they were therefore analyzed together: the endogenous thrombin potential increased 
by 26% (from 756±50.6 to 950±68 nmol thrombin x min), the time to peak decreased by 8% 
(from 19.7±0.4 to 18.2±0.5 min; p= 0.02, and the peak increased by 61% (from 41.2±3.3 to 
66.4±9.4 nM thrombin ; p=0.03) (Figure 11). Thrombin generation was completely abolished by 
PS blockade with lactadherine, but was uninfluenced by TF blockade both before and after the 
meal. (Figure 12). 
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Figure 11: Thrombin generation: Endogenous thrombin potential before (blue) and after (red) the meal.  
 
 
Figure 12: Figure 3: MP-induced thrombin generation without (blue curves) and with PS inhibition by 
lactadherin (green curves) or an anti-TF antibody (red curves) before and after the meal.  
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DISCUSSION  
This thesis focuses on two issues of interest in relation to the cardiovascular risk in diabetes, i.e., 
improving the response to aspirin treatment in high risk patients with  T2DM (study 1), and what 
determines the presence and extent of postprandial platelet activation (studies 2-3) as well as 
microparticle formation (study 4), by evaluating the effects of insulin treatment and by 
comparing T2DM and T1DM patients. 
In study 1 we found an improved laboratory response to aspirin 75 mg twice daily (BID) 
compared to once daily (OD) by two whole blood methods. Until now, three other studies using 
different methods have compared OD and BID aspirin dosing in patients with T2DM and they 
have all shown that BID dosing improves the response to aspirin (Table 2). 
Rocca et al analyzed TxB2 recovery in serum 12-24 hours after aspirin intake in 100 patients with 
T2DM who took aspirin for either primary or secondary prevention and selected patients in the 
upper tertile of Tx recovery (i.e., patients with rapid platelet turnover) for a dose comparison 
(71). Aspirin OD 100 mg BID abolished the increase in TxB2 recovery seen in this subgroup with 
100 mg OD , while 200 mg OD had an intermediate effect.  Aspirin BID had no effect on the 
VerifyNow aspirin assay or on urinary 11-dehydro-TxB2 excretion. Higher platelet recovery after 
aspirin, i.e., a faster platelet turnover, was correlated with MPV, BMI and young age (71). 
The studies by Capodanno et al (72) and Dillinger et al (73) included T2DM patients with stable 
coronary artery disease (CAD). Capodanno found that 81 mg BID or 162 mg BID, improved the 
response to aspirin (VerifyNow Aspirin test, and collagen induced platelet aggregation in PRP) 
as compared to 81mg OD (72). Dillinger found that 75mg BID gave better platelet inhibition than 
150mg OD (light transmission aggregometry with AA and the PFA-100 method in whole blood) 
(73).  
Both Rocca et al and we included patients who received aspirin for either primary or secondary 
prevention. When we planned our study during 2006, aspirin was recommended for 
cardiovascular protection for patients with diabetes, regardless of prior vascular events (16). 
However, we decided to include high risk diabetic patients with micro- and/or macrovascular 
complications who according to DiMinno et al were supposed to have a high platelet turnover, 
and 11/25 patients did not have macrovascular complications (28). The recommendations for 
aspirin use at that time were based on subgroup analysis of large cohorts of high risk patients 
receiving aspirin for either primary or secondary prevention, and the number of diabetic patients 
was relatively low (only 4000 diabetics among 95000 patients) (74). Later on, a controversy 
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regarding aspirin for primary prevention in diabetes rose when some studies dedicated to diabetic 
patients failed to demonstrate efficacy in primary prevention (17-19,75). The current american 
guidelines still recommend aspirin for primary prevention in diabetes for patients whose 10 year 
risk for cardiovascular events is above 10% (21) and the european guidelines recommend aspirin 
for secondary prevention for all DM patients and for primary prevention in selected high risk 
patients (1). If we had performed the study today we would probably have selected secondary 
prevention patients only. However, perhaps BID dosing of aspirin might be able to show greater 
efficacy and thereby increase the rationale for aspirin treatment also in primary prevention. 
We studied a population of patients with T2DM and micro/macrovascular complications, similar 
to the population studied by DiMinno et al (28). However, there was considerable variability in 
the reticulated platelet percentages among our patients, between 6% and 26%, despite this 
selection of patients. We found a strong correlation between the percent reticulated platelets and 
mean platelet volume, as did Rocca et al (71). Our study had a crossover design in which each 
patient served as his/her own control and we did not include a control group of healthy subjects, 
therefore we cannot conclude that diabetic patients indeed have a higher platelet turnover as 
compared to other high risk patients or healthy subjects. Interestingly, the response to BID 
aspirin did not correlate with either MPV or reticulated platelets, and patients could benefit from 
BID dosing of aspirin whether they had low or high reticulated platelets or MPV. In agreement 
with our findings, Dillinger et al found that MPV was not related to an improved response to BID 
aspirin (73). 
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Table 2: Studies of twice daily dosing of aspirin in patients with T2DM. CAD;coronary artery 
disease, OD; once daily, BID; twice daily, WBA; whole blood aggregometry, AA; arachidonic 
acid, LTA; Light transmission aggregometry 
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Grove et al studied patients with stable CAD and found a positive correlation between 
platelet turnover (by flow cytometry) and platelet aggregation in whole blood one hour after 
low-dose (75 mg) aspirin ingestion in 85 patients with T2DM and 92 non-diabetics (23). In 
that study, the level of reticulated immature platelets was correlated with thrombopoetin 
levels, smoking and diabetes in multivariate analysis. However, neither reticulated platelets 
nor MPV differed between patients with stable CAD with or without diabetes (personal 
communication with Grove (23), Therefore, the concept of high platelet turnover in DM 
should be reevaluated.  
We observed differences in the effectiveness of aspirin treatment between platelet 
aggregation in PRP and in whole blood. The nearly complete inhibition of AA induced 
platelet aggregation in PRP suggests that aspirin had reached its target in platelets and that 
our patients had good compliance. At the same time there was clearly residual AA induced 
platelet aggregation in whole blood. These differences in platelet aggregation between PRP 
and whole blood are interesting and have also been observed in another study (76). Whole 
blood is the natural platelet environment, where other blood cells as erythrocytes and 
leukocytes are also present, and may be the most relevant matrix for platelet function studies.  
It is known that platelets interact with leukocytes. Tx and AA can also be produced by other 
blood cells such as monocytes (77) and polymorphonulear cells (78), and can be delivered to 
platelets by transcellular metabolism and bypass platelet COX-1 inhibition. Platelets inhibited 
by aspirin can thus be activated in the presence of monocytes (77), and platelets produced 
more TxB2 in the presence of activated PMN cells (78). Tx can also be formed via COX-2 in 
young/reticulated platelets. Aspirin has a lower affinity to COX-2 which therefore is not 
inhibited by low dose aspirin (64). The newly released large/reactive platelets may be lost 
during centrifugation for the preparation of PRP which could contribute to  the lack of 
platelet activation by AA in PRP despite residual AA responses in whole blood. Finally, 
RBCs which are present in whole blood contain ADP which can activate platelets (79). 
Aggregation in PRP used to be the “gold standard” for studying responses to antiplatelet 
treatment. However, this should probably be reconsidered, and future studies should more 
often concentrate on assays performed in whole blood. 
A higher dose of aspirin has also been suggested to provide better platelet inhibition in DM 
(76). In our study 320 mg OD improved the response to aspirin as compared to 75 mg OD 
when using whole blood aggregometry, but 75 mg BID was more effective than 320 mg OD. 
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Higher doses of aspirin are less attractive since they might increase the systemic bioavailability 
with more COX-2 inhibition leading to reduced PGI2 formation, and higher doses of aspirin are 
also associated with a higher gastrointestinal bleeding risk. Thus, a low BID dose of aspirin may 
be preferable to a higher OD dose both from the efficacy and safety points of view.  
Urinary 11-dehydro TxB2 excretion was reduced by the higher aspirin dose of 320 mg OD, but 
there was only a trend toward a reduction with 75 mg BID (p=0.07) in our study. Rocca et al also 
measured urinary 11-dehydro-TxB2 and found that it was uninfluenced by platelet turnover or by 
dosing of aspirin (up to 200 mg per day) (71) Tx is also produced by other blood cells and 
endothelial cells, and approximately 20% of the stable Tx metabolite excretion in urine is of non-
platelet origin (23,61). Therefore, the reduced TxB2 excretion with the higher dose of aspirin 
could be related to increased systemic bioavailability of aspirin and inhibition of endothelial 
cells, rather than to better platelet inhibition. 
Until now the twice daily dose of aspirin has only been studied in small-scale studies of 
laboratory responses to the drug. Based on these studies which have all shown an improvement in 
the laboratory response to aspirin there should be a place for a clinical trial of BID aspirin for 
secondary prevention in patients with T2DM. Very large studies of thousands of diabetic patients 
will, however, be needed to prove improved clinical outcomes with BID compared to the 
conventional OD dosing of aspirin. In such a study, patients should not be selected according to 
their platelet turnover, since this is very impractical in an ordinary clinical setting, and since also 
patients with a low % reticulated platelets or a low MPV could benefit from BID dosing 
according to our study and that of Dillinger et al (73).  
Possible drawbacks of twice daily use of aspirin are the problems of compliance and safety, 
mainly with regard to gastrointestinal toxicity. Twice daily dosing may, however, also be 
“compliance forgiving” since one missed dose results in a 24 h rather than a 48 h interval until 
the next dose. Twice daily dosing of aspirin has also been studied in patients with essential 
thrombocythemia who have an abnormal megakaryopoesis and a high platelet turnover. In these 
patients aspirin 100 mg BID provided better platelet inhibition as compared once daily dosing 
(80). In addition, the excretion of a stable PGI2 metabolite in urine was not changed supporting 
cardiovascular safety of 100 mg aspirin BID treatment (81). Thus, an outcome study of BID 
aspirin in high risk patients would be of considerable value. Unfortunately, however, such large 
studies require large resources and aspirin is an old and cheap drug with no or very limited 
commercial interest. The likelihood that a large outcome study with BID dosing of aspirin will be 
undertaken is therefore small.  
 30 
 
Postprandial platelet activation  
The second part of this thesis is related to postprandial platelet activation and the mechanisms 
involved. Yngen et al from our group had previously shown thata carbohydrate rich meal 
activates platelets in patients with T2DM (39). Patients were tested, in a randomized cross-
over study ,without any glucose lowering treatment and after taking repaglinide or 
glibenclamide, two medications that are known to increase insulin secretion and reduce 
postprandial glucose levels. In that study, both medicines reduced glucose levels mildly and 
neither attenuated the meal-induced platelet activation. Healthy individuals ingesting the 
same meal had neither postprandial hyperglycemia nor platelet activation (37). We therefore 
hypothesized that a stronger postprandial glucose lowering agent is needed to reduce glucose 
levels sufficiently in T2DM to also prevent postprandial platelet aggregation. 
To our great surprise, the opposite results were obtained. Insulin aspart administered 
immediately before the same carbohydrate rich meal reduced, but did not abolish 
postprandial hyperglycemia and the postprandial platelet activation increased further with 
both insulin doses. In addition, we observed platelet activation following the glucose 
normalization procedure with intravenous insulin that preceded the meal. We concluded that 
postprandial platelet activation is not related to glucose levels but to insulin levels. We then 
compared patients with T1DM who are unable to secrete insulin to patients with T2DM, 
having the same meal but without premeal insulin. Indeed we found that patients with T1DM 
had very high levels of posprandial glucose but no platelet activation, proving that 
postprandial hyperglycemia is not the reason for postprandial platelet activation in diabetic 
patients.  
Table 3 summarizes our results from four carbohydrate rich meal studies in patients with DM 
and healthy individuals.  
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Subjects  
(ref) 
Postprandial 
hyperglycemia 
Postprandial 
insulin elevated 
Postprandial 
platelet activation 
Healthy 
individuals (37) 
No 
Yes 
(not measured in 
the study ) 
No 
T1DM (study 3) Yes (marked) No No 
T2DM 
(37, 39, studies 2-
3) 
Yes Yes Yes 
 
Table 3:  Postprandial glucose, insulin and platelet activation in patients with DM and healthy 
individuals 
 
Platelets carry receptors for insulin (IR) and insulin like growth factor (IGF-R) which share a lot 
of homology (82). A human platelet contains about 570 IR (83) and many more IGF-R  Both 
receptors are transmembrane glycoproteins composed of 2 extracellular subunits and 2 
transmembrane  subunits (82). The  subunit binds ligands and the  subunit has tyrosine 
kinase activity. When insulin binds to the  subunit, it leads to autophosphorylation of the  
subunit, a conformational change and phosphorylation of other proteins. The literature is 
inconsistent with regard to the effects of insulin on platelet activation, as some report platelet 
activation by insulin while others report platelet inhibition or no effect (82-87). It has been 
suggested that physiological or high physiological concentrations of insulin (0.25-2 nmol/L = 26-
288 U/mL) inhibit platelet activity, whereas supraphysiological concentrations (25-200 nmol/L 
= 2600-29000U/mL) enhance platelet activity (84).  
Different mechanisms of platelet inhibition by insulin have been suggested. Based on studies in 
healthy individuals, Ferriera et al suggested that insulin attenuates platelet activation by ADP and 
thrombin by interfering with cAMP suppression through IRS-1 and Gi (83). Hunter et al showed 
that platelets express (IR) homodimers or IR/IGF-R hybrids (82). However, they found no direct 
effect of insulin on platelet activation at physiological concentrations and speculated that this is 
due to the fact that IGF-R is much more abundant and most of the IR is in hybrids which are not 
sensitive to insulin. Anffosi et al (84) suggested that insulin is able to increase both cGMP 
synthesis through guanylate cyclase activation, and cGMP catabolism through phosphodiesterase 
activation. At physiological or slightly supraphysiological concentrations the first phenomenon  
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dominates so that intraplatelet cGMP levels increase and insulin shows antiaggregating 
properties, whereas insulin reduces cGMP levels through phosphodiesterase activation at 
supraphysiological concentrations, leading to platelet activation (84). 
We have consistently found in vitro platelet activating effects of physiological or slightly 
above physiological concentrations of insulin (10-300U/ml) in vitro in healthy individuals 
(87-88) and in patients with T1DM (86), and in vivo postprandial activation with in T2DM 
(37,39). These findings are in agreement with the findings in studies 2 and 3. Even groups 
that have found platelet inhibitory effects of insulin in healthy volunteers did not find that in 
patients with T2DM or obesity. Those patients seem to have “platelet insulin resistance” with 
a loss of the platelet inhibitory responsiveness to insulin (89-91). Our results with markedly 
enhanced platelet activation in the presence of elevated insulin levels in vivo (after the meal, 
or after insulin infusion) in response to the Tx analogue U46119, but only mild enhancement 
of  responses to ADP suggest a role of the Tx pathway in the platelet activating effect of 
insulin. This is a novel mechanism for the effect of insulin on platelets and it would be 
interesting to explore whether aspirin treatment could reduce postprandial platelet activation 
inT2DM.  
The inconsistencies in the literature with regard to the effects of insulin on platelets are not 
understandable at the moment and may result from, e.g., different methods of testing platelet 
activation (flow cytometry in our laboratory and mostly platelet aggregation in PRP in other 
laboratories), different doses of insulin, and/or the complexity of platelet activation with 
different stimuli and response variables. For example fibrinogen binding was decreased when 
stimulated by ADP but increased when stimulated by U46619 in studies 2 and 3 which was 
opposite to all other results and we cannot presently explain this discrepancy.   
The findings of a role of insulin in postprandial platelet activation may be of clinical 
importance considering the findings that insulin treated T2DM patients have a higher ADP 
induced platelet aggregation than T2DM patients not treated with insulin (92) and the 
growing evidence for worsened clinical outcome in patients who receive insulin. In the 
DIGAMI 2 trial the risk of suffering non-fatal myocardial infarction or stroke increased 
significantly with insulin treatment while metformin was protective (93). In a retrospective 
Swedish study based on two registries that included 12500 diabetic patients after coronary 
angiography, T2DM patients treated with insulin who underwent coronary angiography had a 
higher long-term mortality risk (94), and among patients with DM who were treated with 
metformin, the addition of insulin vs a sulfonylurea was associated with an increased risk of  
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suffering a composite endpoint of nonfatal cardiovascular outcomes and all-cause mortality (95).  
Other possible mechanisms that might contribute to the differences in postprandial platelet 
activation between T1DM and T2DM besides the different insulin levels could be related to 
parameters that were not studied such as triglyceride levels which could influence platelet 
activation (96), age differences (patients with T1DM were younger) and insulin resistance. 
Patients with T1DM in our study had lower BMI´s and were less likely to have insulin resistance. 
Insulin may therefore have platelet inhibiting effects in lean T1DM as in healthy subjects but 
there was no postprandial insulin response in the T1DM patients. A study with premeal insulin in 
obese versus non-obese T1DM patients would clarify the question of the role of platelet insulin 
resistance in postprandial platelet activation.  
After obtaining the different results between T1DM and T2DM we tried to recall patients with 
T1DM for another visit with meal intake after taking their regular premeal insulin. Six of the 11 
patients agreed to come, but this group is too small to allow any firm conclusions. Our 
impression is that there was platelet activation also in T1DM patients after receiving insulin. For 
example, stimulation with U46619 increased platelet P-selectin expression from a mean of 
16.7+2.2 to 29.6+8.0% after the meal with premeal insulin (p=0.19), as compared to a slight 
decrease/no change for the same six patients in the previous visit without premeal insulin. Five 
patients showed platelet activation after the meal and one patient who was well trained (a 
marathon runner) and was treated with an insulin pump had results that differed from the others 
with lower insulin levels in plasma and no platelet activation after the meal even with meal 
insulin. A proper meal insulin study comparing lean and obese T1DM patients is of considerable 
interest. 
In vitro incubation of samples from T1DM patients with insulin at similar plasma concentrations 
as the postprandial insulin levels (100 U/ml) in T2DM patients resulted in mild platelet 
activation both before and after the meal (figure 10). Reasons behind the smaller effect of insulin 
in vitro compared to in vivo could be other effects of insulin occurring in vivo, or the time of 
platelet exposure to insulin – only 20 min in vitro versus 90 min in vivo. However, in vitro 
systems are often less responsive than in vivo systems also from a more general point of view. 
The impression from the above-mentioned results is thus that platelets from patients with T1DM 
can be activated postprandially by insulin, and it would be interesting to further characterize the 
platelet responses to insulin in T1DM. 
Boden et al performed clamp studies in healthy volunteers and in patients with T2DM (97-98). 
They observed that selective hyperinsulinemia increased tissue factor (TF) procoagulant activity 
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by 30%, and that hyperglycemia and hyperinsulinemia had additive effects as TF 
procoagulant activity increased by 80% when they were combined. If the same is true for 
platelet activation, it is comprehensible why patients with T2DM in our study had marked 
platelet activation with both hyperinsulinemia and postprandial hyperglycemia. We have 
shown in patients with T1DM that postprandial hyperglycemia alone does not cause 
postprandial platelet activation, but hyperglycemia might still contribute to platelet activation 
seen in the presence of hyperinsulinemia. Clamp studies focused on platelet activation would 
be able to solve this question. 
 
Postprandial microparticle formation  
The meal induced increased MP formation in both patients with T1DM and T2DM. The MPs 
were derived from all cell types, platelets, monocytes and endothelial cells. Endothelial cells 
released E selectin positive MPs which is a marker for endothelial activation (99), but not 
VE-cadherin (CD 144) positive EMPs. VE-cadherin is a cell adhesion glycoprotein located in 
the tight junction between endothelial cells and perhaps greater endothelial damage may be 
required for its release. Alternatively, the release of VE-cadherin
+
 MPs may be related to the 
content of the meal, as it was elevated in T2DM patients after two consecutive fat rich meals 
in another study (51). Monocytes carrying TF increased in both patients with T1DM and 
T2DM. Monocytes are the main cells that carry tissue factor in blood (100) and activated 
platelets are able to bind TF from MMPs through P-selectin on platelets and PSGL-1 on 
MMPs (100-101).  
All types of platelet derived MPs increased in T1DM (PS
+
, P-selecin
+
 and TF
+
), while only 
TF
+
 PMPs were increased significantly in T2DM. These results were unexpected as we 
observed postprandial platelet activation in T2DM and not T1DM in this study (study 3). One 
explanation could be that increased platelet activation results in higher MP formation but also 
higher MP consumption, or adherence of MPs to other cells (102). Of note, both platelet and 
monocyte counts decreased after the meal which could possibly reflect their consumption. 
Decreases in monocyte and lymphocyte counts have also been observed in healthy volunteers 
after a light meal (103). Another explanation for the increased postprandial PMP levels in 
T1DM is the complexity of biological responses of the coagulation system; it could be that 
MP release is related to high postprandial glucose levels and not to insulin levels (contrary to 
the platelet activation response) and therefore their levels tended to increase more markedly 
in T1DM in this study.  
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The increment in MPs after the meal also resulted in increased MP-dependent thrombin 
generation. The CAT assay was modified and was performed without adding phospholipids or 
tissue factor to assure that the prothrombotic potential is driven by the MPs. Blocking PS 
expressed on the MPs abolished the thrombin generation, reflecting the role of the negatively 
charged surface of MPs in promoting thrombin generation, while an antibody towards TF did not 
influence the thrombin generation. The number of MPs carrying TF was relatively small as 
compared to the number of PS
+ 
MPs (table 1), and perhaps the role of MPs carrying TF is to 
deliver TF to the site of injury where it can be activated while it may present in a non-functional 
form on circulating MPs (104). Nonetheless, the postprandial increases in MPs with procoagulant 
activity due to PS exposure are a novel prothrombotic mechanism which may contribute to the 
increased cardiovascular risk of DM patients. 
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CONCLUSIONS  
 
The following conclusions can be drawn from this work: 
 Twice daily dosing of aspirin 75 mg improves the laboratory response to aspirin in whole 
blood, as compared to the regular once daily dose of 75 mg or to a higher dose of 320 mg 
once daily, in high risk patients with T2DM and micro/macrovascular complications. 
 The improved laboratory response to twice daily dosing of aspirin is not related to the 
turnover of platelets, as both patients with low and high turnover could benefit from twice 
daily use of aspirin.  
 Reducing postprandial glucose levels by rapid "meal insulin" did not reduce postprandial 
platelet activation in patients with T2DM. On the contrary, use of premeal insulin increased 
the postprandial platelet activation in T2DM. 
 When no insulin is given prior to the meal, patients with T1DM and no insulin secretion do 
not have postprandial platelet activation, despite very high glucose levels. 
 Postprandial platelet activation is seen mainly when the Tx pathway of platelets is stimulated 
and is related to high insulin levels rather than to hyperglycemia in patients with DM.  
 Prothrombotic microparticles derived from platelets, monocytes and endothelial cells are 
released after the meal in patients with both T1DM and T2DM.  
 Postprandial microparticle formation may be related to postprandial hyperglycemia and not to 
hyperinsulinemia, since patients with T1DM had low insulin and high postprandial glucose 
levels and similar or even increased microparticle release as compared to T2DM patients. 
 Postprandial platelet activation and release of procoagulant microparticles may contribute to 
the increased cardiovascular risk of T2DM patients. Further studies are needed to clarify the 
role of insulin in postprandial platelet activation in T1DM patients.  
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